Head-To-Head Survey: Guardian Pharmacy Services (NYSE:GRDN) versus VYNE Therapeutics (NASDAQ:VYNE)

VYNE Therapeutics (NASDAQ:VYNE) and Guardian Pharmacy Services (NYSE:GRDN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Valuation and Earnings

This table compares VYNE Therapeutics and Guardian Pharmacy Services”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570,000.00	33.29	-$26.48 million	($0.38)	-74.54
Guardian Pharmacy Services	$1.45 billion	1.40	$49.22 million	$0.83	49.17

Guardian Pharmacy Services has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

83.8% of VYNE Therapeutics shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by company insiders. Comparatively, 33.0% of Guardian Pharmacy Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for VYNE Therapeutics and Guardian Pharmacy Services, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1	3	0	0	1.75
Guardian Pharmacy Services	0	2	7	0	2.78

Guardian Pharmacy Services has a consensus target price of $42.83, indicating a potential upside of 4.96%. Given Guardian Pharmacy Services’ stronger consensus rating and higher possible upside, analysts plainly believe Guardian Pharmacy Services is more favorable than VYNE Therapeutics.

Profitability

This table compares VYNE Therapeutics and Guardian Pharmacy Services’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Guardian Pharmacy Services	3.64%	30.72%	15.99%

Risk & Volatility

VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, Guardian Pharmacy Services has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500.

Summary

Guardian Pharmacy Services beats VYNE Therapeutics on 11 of the 14 factors compared between the two stocks.

About VYNE Therapeutics

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.